Pipeline

We are leveraging our proprietary kinase switch control inhibitor platform to develop a pipeline of highly selective, potent small molecule drug candidates that directly inhibit activation of kinases implicated in the growth and spread of cancers. We currently retain global development and commercialization rights to our drug candidates.

Tumor-Targeted Programs and Indications Pre-Clinical Phase 1 Phase 2 Phase 3 Global Rights
DCC-2618 KIT & PDGFRα*

GIST

 

Proficient Life Pharma
PDGFRα

GBM & Glioma

 

Proficient Life Pharma
KIT (D816V)

Advanced Systemic Mastocytosis

 

Proficient Life Pharma
KIT & PDGFRα

Other Cancers

 

Proficient Life Pharma
Research Program Undisclosed

Cancer Metabolism
Proficient Life Pharma
Immunokinase Programs and Indications
Rebastinib TIE2

Breast Cancer + Chemotherapy1

 

Proficient Life Pharma
TIE2

Checkpoint Inhibitor Combination

 

Proficient Life Pharma
DCC-3014 CSF1R

Solid Tumors & Hematological Malignancies

 

Proficient Life Pharma
CSF1R

Checkpoint Inhibitor Combination

 

Proficient Life Pharma
Research Program Undisclosed

Immunokinase
Proficient Life Pharma
Tumor-Targeted Programs and Indications
Phase Global Rights
DCC-2618
KIT & PDGFRα*

GIST

Phase 1 Proficient Life Pharma
PDGFRα

GBM & Glioma

Phase 1 Proficient Life Pharma
KIT (D816V)

Advanced Systemic Mastocytosis

Phase 1 Proficient Life Pharma
KIT & PDGFRα

Other Cancers

Phase 1 Proficient Life Pharma
Research Program
Undisclosed

Cancer Metabolism
Pre-Clinical Proficient Life Pharma
Immunokinase Programs and Indications
Phase Global Rights
Rebastinib
TIE2

Breast Cancer + Chemotherapy1

Phase 1 Proficient Life Pharma
TIE2

Checkpoint Inhibitor Combination

Phase 1 Proficient Life Pharma
DCC-3014
CSF1R

Solid Tumors & Hematological Malignancies

Phase 1 Proficient Life Pharma
CSF1R

Checkpoint Inhibitor Combination

Phase 1 Proficient Life Pharma
Research Program
Undisclosed

Immunokinase
Pre-Clinical Proficient Life Pharma
*Pivotal Phase 3 study initiated in 4th line GIST
Note: (1) Investigator initiated and sponsored research